PHARMAC seeks clinical feedback on its cost-utility analysis methodology

New Zealand Medical Journal

Volumn 119, Issue 1239, 2006, Pages

  Grocott, Rachel ^a   Moodie, Peter ^a  

^a Pharmaceutical Management Agency   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; HEALTH CARE FINANCING; HUMAN; INTERNET; LONGEVITY; MEDICAL DECISION MAKING; METHODOLOGY; PHARMACEUTICAL CARE; PRESCRIPTION; QUALITY OF LIFE; DRUG CONTROL; LETTER; NEW ZEALAND; PHARMACOECONOMICS;

COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; ECONOMICS, PHARMACEUTICAL; HUMANS; NEW ZEALAND;

EID: 33747320520     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Milne R. Valuing prevention: discounting health benefits and costs in New Zealand. N Z Med J. 2005 May 6;118(1214). URL: http://www.nzma.org.nz/journal/118-1214/1443/
2. Grocott R, Metcalfe S. Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. N Z Med J. 2005 Oct 7;118(1223). URL: http://www.nzma.org.nz/journal/118-1223/1690/
3. Metcalfe S, Moodie P, Grocott R, Wilkinson T. PHARMAC responds on TNF inhibitors for inflammatory arthritis. N Z Med J. 2005 Dec 16;118(1227). URL: http://www.nzma.org.nz/journal/118-1227/1799/
4. Simpson A. What's happening in PHARMAC - where do all the submissions go? On the trail of gemcitabine. N Z Med J. 2005 Nov 11;118(1225). URL: http://www.nzma.org.nz/journal/118-1225/1733/
5. Crausaz S, Metcalfe S. PHARMAC's response on gemcitabine and transparency. N Z Med J. 2005 Nov 11;118(1225). URL: http://www.nzma.org.nz/journal/118-1225/1741/
6. Hamilton D. Evidence, economics, and emotions: the case for temozolomide. N Z Med J. 2005 Dec 16;118(1227). URL: http://www.nzma.org.nz/journal/118-1227/1774/
7. Ellis P, Mulder R, Porter R. PHARMAC and treatment of bipolar depression - the limits of utilitarianism. N Z Med J. 2006 Mar 31;119(1231). URL: http://www.nzma.org.nz/journal/119-1231/1924/
8. PHARMAC. Operating policies and procedures of the Pharmaceutical Management Agency. ("PHARMAC"), 2nd edition. January 2001. http://www.pharmac.govt.nz/pdf/opps.pdf. Section 2.2 Decision Criteria.
9. Metcalfe S, Brougham M, Moodie P, Grocott R. PHARMAC responds to Richard Milne on discounting health benefits and costs. N Z Med J. 2005 Jul 29;118(1219). URL: http://www.nzma.org.nz/journal/118-1219/1601/
10. Milne R. Richard Milne responds to PHARMAC on discounting future health benefits and costs. N Z Med J. 2005 Aug 12;118(1220). URL: http://www.nzma.org.nz/journal/118-1220/1620/